BioSpace News Archive

Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the second quarter and six months ended June 30, 2022.

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the second quarter of 2022 and provided a corporate update.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2022 and corporate updates, before market open on Thursday, August 11, 2022.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended June 30, 2022 and provided operational updates.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced financial results for the second quarter that ended June 30, 2022 and provided a business update.

iHealthScreen Inc. completed a prospective study for early diagnosis of AMD in primary care settings.

Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported financial results and corporate updates for the second quarter ended June 30, 2022.

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report top-line Phase 3 data from its ENHANCE-2 (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) trial of nebulized ensifentrine and its financial results for the second quarter ended June 30, 2022 on August 9, 2022.

Annovis Bio, Inc. today announced second quarter financial results for the quarter ended June 30, 2022, and reviewed recent accomplishments.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the second quarter ended June 30, 2022 and provides a corporate update.